Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prohost Letter #406

March 13, 2017 0

Prohost Letter #406 A Special Prohost Issue SYNOPSIS REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES VERTEX …

Prohost Letter #405

March 10, 2017 0

Prohost Letter #405 Synthetic Biology (3) We have already decided upon becoming shareholders the day synthetic …

Ionis Drug Volanesorsen’s Reward Outweighs the Mitigated Risk

March 8, 2017 0

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS), announced positive results from the pivotal …

Lexicon Pharmaceuticals: Cultivating the Fruits From Years of Lucrative Research

March 6, 2017 0

A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg …

Why Would a Specific Rheumatoid Arthritis Drug Treat Aggressive Cancers? Read Also: Other Important News

March 3, 2017 0

An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for …

Kite Pharma’s CAR-T Therapy Passed the Test with High Grades

March 2, 2017 0

We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the …

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

February 27, 2017 0

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of …

Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center

February 24, 2017 0

Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania. …

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

February 23, 2017 0

Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise …

Agenus: Why Canceling Prophage Trial Should Not be Concerning

February 22, 2017 0

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore …

Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

February 21, 2017 0

Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other …

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

February 17, 2017 0

About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

February 14, 2017 0

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

February 14, 2017 0

Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …

Interpreting Portola Pharmaceuticals’ News

February 9, 2017 0

The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …

Gilead Sciences: A Case Study

February 9, 2017 0

Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the …

Prohost Letter #404 Part 2

February 6, 2017 0

Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of …

How Good Is Xoma’s Good News?

February 4, 2017 0

XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 …

Companies Targeted for Takeover Yet Can Thrive on their Own

February 2, 2017 0

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order …

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

January 30, 2017 0

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Prohost Letter #406

Prohost Letter #405

Ionis Drug Volanesorsen’s Reward Outweighs the Mitigated Risk

Lexicon Pharmaceuticals: Cultivating the Fruits From Years of Lucrative Research

Why Would a Specific Rheumatoid Arthritis Drug Treat Aggressive Cancers? Read Also: Other Important News

Kite Pharma’s CAR-T Therapy Passed the Test with High Grades

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

Agenus: Why Canceling Prophage Trial Should Not be Concerning

Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

Interpreting Portola Pharmaceuticals’ News

Gilead Sciences: A Case Study

Prohost Letter #404 Part 2

How Good Is Xoma’s Good News?

Companies Targeted for Takeover Yet Can Thrive on their Own

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms